Ocuphire Pharma, Inc. OCUP NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

51/100

1/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Ocuphire Pharma, Inc. (OCUP) , 前瞻盈利收益率 14.25%.

本页证实的标准:

VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。
前瞻市盈率 7.0

SharesGrow 综合评分： 48/100 其中 1/7 项标准通过。

SharesGrow 7-Criteria Score

51/100

SG Score

View full scorecard →

—

价值

N/A

No coverage

✓

未來

100/100

Analyst consensus

→ Forecast

✗

过去

25/100

→ Income

健康

67/100

Debt-to-Equity & liquidity

→ Health

护城河

46/100

→ Income

✗

成长

15/100

→ Income

—

收入

N/A

No coverage

估值概览 — OCUP

估值倍数

P/E (TTM)0.0

前瞻 P/E7.0

PEG 比率N/A

前瞻 PEG0.00

P/B 比率0.00

P/S 比率0.00

EV/EBITDA0.0

每股数据

EPS (TTM)$-0.80

前瞻 EPS（预估）$0.17

每股账面价值$0.00

每股营收$0.00

每股自由现金流$0.00

收益率与内在价值

盈利收益率N/A

Forward Earnings Yield14.25%

股息收益率0.00%

EPS：实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year	EPS（稀释）	营收	净利润	净利润率
2016	$-20.55	$0.00	$-9.31M	-
2017	$-44.33	$0.00	$-25.29M	-
2018	$-20.95	$0.00	$-14.37M	-
2019	$-10.56	$0.00	$-7.51M	-
2020	$-6.75	$0.00	$-31.48M	-
2021	$-3.81	$589K	$-56.53M	-9598.3%
2022	$0.87	$39.85M	$17.89M	44.9%
2023	$-0.46	$19.05M	$-9.99M	-52.4%
2024	$-2.15	$0.00	$-57.53M	-
2025	$-0.80	$0.00	$-49.59M	-